Zentiva buying Romanian pharma company Solacium
Zentiva Group and Siyiara Enterprises have signed a shared purchase agreement for the acquisition of Romanian based pharmaceutical company Solacium, together with its subsidiary Be Well Pharma.
Solacium is currently part of the Dr Max Group and owned by Siyiara Enterprises together with Trasca Alexandru-Tony.
Nick Haggar, chief executive of Zentiva, stated: "Zentiva is delighted to confirm the signing of its first acquisition following the carve out from Sanofi in the last quarter of 2018. Solacium complements our existing generic medicines business and grows our OTC capability offering for patients and consumers in Romania and."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze